ArticleHeart rhythm O22025
Clinical epidemiology of atrial fibrillation in heart failure in Abeokuta, Nigeria.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia seen in clinical practice that requires treatment. Data on the burden of AF in patients with heart failure (HF) are generally lacking in Nigeria and Africa. Objective: This study aimed to characterize the clinical and echocardiographic profiles of patients with AF in our clinical practice. Methods: An observational hospital-based study was conducted on patients with AF in the setting of HF seen at an urban tertiary hospital in Nigeria over 9 months. All patients had both clinical and echocardiographic evaluations. Results: A total of 100 cases of AF in HF were recruited for the study. Of these, 54 were men and 46 women. The mean age of the participants was 55.7 (13.3) years (male: 58.8 [10.5], female: 52.1 [15.4] years). The age range was 18 to 86 years for the cohort (male: 32-86 years, female: 18-79 years). Most participants were older than 40 years (88%). Hypertensive heart disease was the most common risk factor, although rheumatic heart disease and thyroid heart disease played a major role in women and most required anticoagulation. Conclusion: AF in HF in our setting occurred at a younger age compared with data from Western Europe and North America. Women were diagnosed at a younger age because of the risk factors. Hypertensive heart disease was the most common risk factor, and most patients required anticoagulation. Studies are needed to determine the impact of AF on the outcome of HF in our setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.